New hope for kids with stubborn hives: dupixent studied
NCT ID NCT05526521
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug dupilumab (Dupixent) in 15 children aged 2 to 12 who have chronic spontaneous urticaria (CSU), also known as long-lasting hives, that didn't get better with antihistamines. The main goals were to check how the drug behaves in the body and to see if it's safe. The children received injections for 24 weeks and were followed for 12 more weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dupilumab (Dupixent)
What this could lead to
If it works, this could offer a new treatment option for children with chronic hives that don't respond to standard antihistamines.
What could go wrong
This is a small, single-arm study with only 15 participants, so results may not apply to all children. It primarily looked at safety and drug levels, not how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Childrens Health Physicians Site Number : 8400017
Hawthorne, New York, 10532, United States
-
Childrens Hospital Medical Center of Akron- Site Number : 8400020
Akron, Ohio, 44308, United States
-
Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400001
Cincinnati, Ohio, 45229-3026, United States
-
Columbia University Irving Medical Center Site Number : 8400003
New York, New York, 10032, United States
-
Investigational Site Number : 1240001
Montreal, Quebec, H4A 3J1, Canada
-
Investigational Site Number : 1240007
Hamilton, Ontario, L8S1G5, Canada
-
Investigational Site Number : 1240009
Calgary, Alberta, T2W 4X9, Canada
-
Investigational Site Number : 1240010
Edmonton, Alberta, T5J 3S9, Canada
-
Investigational Site Number : 3920001
Yokohama, Kanagawa, 232-8555, Japan
-
Investigational Site Number : 3920002
Tsu, Mie-ken, 514-0125, Japan
-
Monroe Carell Jr. Childrens Hospital at Vanderbilt- Site Number : 8400005
Nashville, Tennessee, 37232, United States
-
Pediatric Dermatology of Miami Site Number : 8400015
Coral Gables, Florida, 33146, United States
-
Treasure Valley Medical Research Site Number : 8400019
Boise, Idaho, 83706, United States
-
Vital Prospects Clinical Research Institute, P.C.- Site Number : 8400002
Tulsa, Oklahoma, 74136, United States
-
Washington University School of Medicine- Site Number : 8400004
St Louis, Missouri, 63110, United States